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Abstract We report a 26-year-old female patient who
was diagnosed within 4 years with chest sarcoma, lung
adenocarcinoma, and breast cancer. While her family his-
tory was unremarkable, DNA sequencing of TP53 revealed
a germline de novo non-sense mutation in exon 6
p.Arg213X. One year later, she further developed a con-
tralateral ductal carcinoma in situ, and 18 months later a
jaw osteosarcoma. This case illustrates the therapeutic
pitfalls in the care of a young cancer patient with TP53 de
novo germline mutations and the complications related to
her first-line therapy. Suggestion is made to use the less
stringent Chompret criteria for germline TP53 mutation
screening. Our observation underlines the possibly nega-
tive effect of radiotherapy in generating second tumors in
patients with a TP53 mutation. We also present a review of
six previously reported cases, comparing their cancer
phenotypes with those generally produced by TP53
mutations.
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Introduction
Li-Fraumeni syndrome (LFS) is one of the most severe
forms of familial cancer susceptibility syndrome, charac-
terized by an early age of tumor onset and a wide tumor
spectrum. According to its first description [1], diagnosis
should be suspected in the presence of a bone or soft tissue
sarcoma in a patient under 45 years of age and a family
history with a first-degree relative with any cancer under
45 years, or a sarcoma at any age. However, LFS is rarely
diagnosed in routine clinical practice, and the French LFS
working group has elaborated practical criteria (Chompret
criteria, Table 1), which were recently updated [2]. These
criteria are less stringent than the original LFS criteria [1]
and have a higher sensitivity that could allow more cases to
be detected.
No other genes than TP53 have been convincingly
associated with LFS [3]. Using current techniques
(sequence analysis, deletion testing), TP53 mutation is
detected in about 70% of LFS families [4]. Molecular
diagnosis of these cases is critically important to ensure an
appropriate medical follow-up and to avoid inappropriate
cancer treatment such as radiation therapy. De novo
mutations of TP53 represent a clinical pitfall, since the
mutational status is not suspected at the time of first cancer
diagnosis.
We report here a case of a woman harboring a de novo
TP53 mutation, diagnosed with a chest wall sarcoma, who
subsequently developed lung and breast cancer, one of
them in the radiation fields, and later contralateral ductal
carcinoma in situ (DCIS) and jaw osteosarcoma.
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Report
A 29-year-old woman with a personal history of chest wall
sarcoma and second primary lung adenocarcinoma was
referred to the oncogenetic clinic for a suspicion of LFS.
Three years earlier, she presented a right chest wall lesion
beneath the right breast. Biopsy of the lesion revealed a
low-grade spindle cell sarcoma. She was treated with a
wide surgical excision, axillary lymph node dissection, and
adjuvant radiation to the right chest wall. She received
50 Gy in 25 fractions over 37 days. The radiation field
included the outer quadrants of the right breast that
received 80% of the radiation dose (Fig. 1).
Twenty-seven months later, a follow-up thoracic and
abdominal CT-scan revealed a pulmonary nodule in the
superior segment of the left inferior lobe (Fig. 1). The patient
underwent a diagnostic wedge resection of the pulmonary
nodule, and pathology revealed a 4-mm bronchioloalveolar
carcinoma. Of note, the patient had never smoked.
Family history (Fig. 2) disclosed a maternal aunt with a
choledochal cancer at age 52 and a sister of her grand-
mother affected with colon cancer at age 79. The classical
diagnostic criteria of a LFS were not fulfilled, but the
occurrence of a sarcoma and lung bronchioalveolar cancer
before age 46 years met the updated Chompret criteria,
prompting molecular genetic screening for a TP53 germ-
line mutation. After obtaining the patient’s written
informed consent, a peripheral blood sample was taken to
perform analysis of the TP53 gene from genomic DNA.
Following PCR amplification and bidirectional sequencing
of all coding exons (including intron/exon junctions) of the
TP53 gene (Ensembl-ID: ENSG00000141510), a non-
sense c.637C [ T (p.Arg213X) mutation in exon 6 was
identified. Sequencing of exon 6 in her parents and her
brother showed no such variant, indicative of a de novo
mutation in the patient.
Thirty-nine months after the initial sarcoma diagnosis
and at the same time of the molecular genetic confirmation
Table 1 2009 Chompret criteria for germline TP53 mutation
screening
I. Proband with tumor belonging to LFS tumor spectrum (e.g., soft
tissue sarcoma, osteosarcoma, brain tumor, premenopausal breast
cancer, adrenocortical carcinoma, leukemia, lung
bronchoalveolar cancer) before age 46 years AND at least one
first- or second-degree relative with LFS tumor (except breast
cancer if proband has breast cancer) before age 56 years or with
multiple tumors; OR
II. Proband with multiple tumors (except multiple breast tumors),
two of which belong to LFS tumor spectrum and first of which
occurred before age 46 years; OR
III. Patient with adrenocortical carcinoma or choroid plexus tumor,
irrespective of family history
LFS Li-Fraumeni syndrome
Fig. 1 a Isodose at level of the subsequent lung cancer. b Isodose at
level of the subsequent breast cancer. c Contrast enhanced axial chest
CT image showing a pulmonary nodule in the superior region of the
left inferior lobe. d Contrast enhanced (Gadolinium) axial T1-
weighted MRI showing the tumor in the upper-outer quadrant of the
right breast
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of the LFS, the patient presented an upper-outer quadrant
lump of her right breast on clinical examination (Fig. 1).
Breast magnetic resonance imaging showed a 2-cm Gad-
olinium-enhanced lesion, and a biopsy confirmed a ductal
carcinoma of the breast. Mastectomy of the right breast
with sentinel lymph node biopsy was performed. The
pathology disclosed a 1.8 cm in size, poorly differentiated
infiltrating ductal carcinoma, with a negative staining for
estrogen and progesterone receptors, but a positive staining
for the epidermal growth factor receptor 2. The staging
work-up (chest and abdomen CT-scan, bone scan, and liver
MRI) was negative. A combined adjuvant treatment with
docetaxel, carboplatin, and trastuzumab was initiated.
However, the patient refused to continue her treatment
after completion of two cycles.
One year later, during the follow-up evaluation, breast
MRI showed a 10-mm contrast enhancement in the upper-
outer quadrant of the left breast. The patient refused a
biopsy and requested a mastectomy, which was performed
with sentinel nodes biopsy. The pathological report con-
firmed a 35-mm large DCIS. Sentinel nodes was negative.
No additional treatment was proposed. Eighteen months
later, jaw pain led to the diagnosis of an osteoblastic bone
lesion. A PET-scan (positron emission tomography) did not
reveal metastases but strengthen the suspicion of a new
primary cancer. Histological analysis of the lesion dis-
closed an intermediate grade 2 differentiated osteosarcoma.
The patient began neoadjuvant chemotherapy. She is now
32 years old.
Discussion
Using the less stringent Chompret criteria, we have iden-
tified a patient harboring a TP53 de novo mutation. In the
initial French cohort, a TP53 mutation was identified in
only 17% of the families, using the first Chompret criteria
[5]. In contrast, in a recent Spanish cohort, 95% of patients
(71/75) with a TP53 mutation met the new Chompret cri-
teria [6]. Clinical utility of the new criteria has been con-
firmed by many authors who also reported TP53 mutations
in young patients with malignancies typical for LFS, but
without a pathognomonic family history fulfilling the LFS
criteria [7–9]. For example, in a study of 14 cases of
childhood adrenocortical tumors, most germline TP53
mutations carriers did not have a family history fulfilling
the classic LFS criteria, leading to the hypothesis of a de
novo mutation or a low penetrance phenotype [10]. Our
patient is another perfect example where younger patients
(\46 years of age) afflicted with multiple primary cancers
should be strongly considered for TP53 genetic testing
even without a positive family history.
Given the very aggressive phenotype observed in our
patient, it is unclear if the p.Arg213X TP53 mutation could
be responsible for that particular phenotype. The
p.Arg213X TP53 mutation is a non-sense mutation located
in exon 6 and has been reported in 287 tumors. Most of the
reported somatic and germline TP53 mutations are mis-
sense mutations; only 6% are represented by non-sense
mutations. The translated p53 protein, if not subjected to
non-sense-mediated decay, is truncated and has lost most
of the DNA-binding domains that are located downstream
of amino acid 213. In the IARC TP53 mutations database
(http://www-p53.iarc.fr/p53main.html database version R14,
November 2009) [11], the p.Arg213X mutation has been
reported in 6 families [3, 9, 10, 12–17]. Five of the six
articles report clinical and family data in sufficient details
and are summarized in Table 2. In one report, the exact
relative degree is not mentioned [3]. Finally, in all reported
families, genetic testing of relatives is not reported.
Trahair et al. recently reported a female patient who had
DCIS at age 30 and 34, low-grade astrocytoma at age 36,
and spindle cell sarcoma at age 36 [17]. This case report
shares many similarities with ours. These two patients are
both female, young at first cancer diagnosis (26 and
30 years, respectively), and both had several primary
tumors. The case reported by Trahair is a not a de novo
mutation, since many family members presented typical
LFS cancers.
The usual phenotype–genotype correlation studies have
focused on TP53 mutation presence, location, or type of
mutation. An IARC database study of families fulfilling the
LFS criteria demonstrates that age at breast cancer diag-
nosis is younger if a TP53 mutation is present. Brain
Fig. 2 Pedigree of the p.Arg213X TP53 family: The numbers
indicate the current age of the patient and the age at cancer diagnosis,
the gray squares indicate the wild-type status, the black circle
indicates the mutated status; DCIS ductal carcinoma in situ
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tumors are associated with missense TP53 mutations
located in the DNA-binding loop that are in contact with
the minor groove of DNA; adrenal gland carcinomas with
missense mutations located in the loops opposing the
protein–DNA contact surface and null phenotype (absence
of the protein or loss of function) with earlier onset brain
tumors [18]. The most significant defect is loss of function
because large deletions encompassing the whole TP53
gene have been found in LFS families with aggressive
features [19]. The p.Arg213X TP53 mutation causes the
lost of most of the DNA-binding domains that are located
downstream of amino acid 213, which could explain the
severe phenotype of our case.
Besides TP53 mutations, other genes can act as genetic
modifiers. Many other genetic modifiers or other mecha-
nism, not yet available for clinical practice, have been
recently identified in LFS families. Polymorphic genetic
variants in the p53 stress response pathway could deter-
mine an individual’s susceptibility to cancer. In the p53
pathway, the MDM2 gene encodes an important negative
regulator of p53. A single nucleotide polymorphism in the
promoter region of MDM2 (SNP309) leads to a functional
attenuation of p53. In 88 LFS patients harboring a patho-
genic TP53 mutation, presence of SNP308 was associated
with an earlier tumor onset [20].
DNA rearrangements, such as DNA copy number vari-
ation (CNVs), can also predispose cancer development
when they encompass, overlap, or disrupt dosage-sensitive
genes. TP53, as guardian of the genome, is involved in the
very processes known to give rise to CNVs, such as sup-
pression of homologous recombination [21]. Genomic
CNVs analysis in a LFS cohort using high-density oligo-
nucleotide arrays has shown that TP53 mutation carriers
displayed a significant increase in CNVs than in TP53
wild-type LFS patients [22].
Among the factors described above, the loss of the
DNA-binding domains located downstream of amino acid
213 explains the high number of primary cancers in our
patient. To the best of our knowledge, no specific TP53
mutation or modifying genes have explained this ‘‘multiple
cancers’’ phenotype. We are aware of only one case report
which showed the existence of a double pathogenic
mutation of TP53 and BRCA2 [23]. The patient was
identified through systematic BRCA1, BRCA2, TP53,
CDKN2A germline mutation screening of 82 patients
diagnosed with breast cancer and melanoma. A coexisting
TP53 mutation and BRCA2 germline mutation was iden-
tified. This patient had developed 6 different primary
cancers by age 70.
Finally, we have to strongly consider the potential del-
eterious influence of the radiotherapy in the rapid devel-
opment of second primary cancers. High sensitivity to
radiation-induced cancers has been reported in vitro [24]
and in many TP53 mutation carriers series [25, 26]. In the
largest series of 200 Li–Fraumeni syndrome family mem-
bers diagnosed with cancer, 30 had multiple primary can-
cers and 8 cases occurred in radiation fields at 3 to 22 years
after the treatment [27]. TP53 is involved in various cel-
lular processes such as the regulation of DNA repair and
programmed cell death. Our patient presented a lung can-
cer close to the radiation fields 27 months after radiother-
apy, a right breast cancer in the irradiated field 39 months
Table 2 Cases with a p.Arg213X mutation as reported in the IARC TP53 mutations database
Reference Type of cancer (index case)
(age at diagnosis (years))
Family history (cancer type (relative age))
Frebourg [15] Breast (27) Colon (N 9)
Reifenberger [16] Cerebral PNET (\1) Cerebral PNET (S 5), ovary (M ?), brain (U 14, U 30),
other (colon, leukemia)
Varley [10] Adrenocortical (\2) Brain (GM 42)
Vahteristo [16] Breast (28) Sarcoma (64), melanoma (67), lung (75)a
Wong [9] Colon (9) Gastric (M 29), sarcoma (GFm 17), breast (Am 27)
Trahair [17] Rhabdomyosarcoma (2) Breast and other cancersb (M 30, 34), fibrosarcoma
(GFm 43), ACC (GCm 8), esophageal (GUm 40), liver (GGFm 20)
Our case Sarcoma (26)
Lung (28)
Breast (29)
Contralateral DCIS (30)
Osteosarcoma (32)
A aunt, ACC adrenocortical cancer, C cousin, DCIS ductal carcinoma in situ, G grand, m maternal, M mother, N niece, p paternal, PNET
primitive neuroectodermal tumor, S sibling, U uncle
a Relatives degree were not reported
b Mother had DCIS at age 30 and 34, low-grade astrocytoma at age 36, spindle cell sarcoma at age 36
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after radiotherapy, as well as a left DCIS also close to the
radiation fields 53 months after radiotherapy. This expo-
sure to radiation therapy probably explains the short time
elapsed between the four primary cancers in our patient.
The jaw osteosarcoma, the fifth primary cancer, is the only
one to be located outside of the chest and occurred 6 years
after the chest sarcoma. This latter time interval corre-
sponds better to the usual occurrence time of a second
primary cancer in TP53 families [18].
In summary, this case report illustrates the difficulties in
making a definitive diagnosis of LFS in patients lacking a
positive family history and also the dangers of treating their
primary tumors with radiotherapy when no proper genetic
diagnosis has been made. In a near future, availability of
high throughput technologies will allow more rapid genetic
testing. Thus, patients at risk could be diagnosed earlier as
carrier of detrimental gene mutations.
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